Skip to main content

Table 2 Base-case analysis expected costs and test performance

From: A PCR-based diagnostic testing strategy to identify carbapenemase-producing Enterobacteriaceae carriers upon admission to UK hospitals: early economic modelling to assess costs and consequences

Strategy Expected cost per patient (£) True positives (%) False positives (%) True negatives (%) False negatives (%)
Culture testing 2166.37 0.6 18.7 80.7 0.0027
PCR testing 1704.24 0.6 3.4 96 0.024
Cost difference with PCR testing (£) −462.13